Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X

被引:36
作者
Sun, YM
Jin, DY
Camire, RM
Stafford, DW [1 ]
机构
[1] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA
[2] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA
关键词
D O I
10.1182/blood-2005-06-2495
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previously we reported that we could increase the fraction of carboxylated factor X by reducing the affinity of the propeptide for its binding site on human gamma glutamyl carboxylase. We attributed this to an increased turnover rate. However, even with the reduced affinity propeptide, when sufficient overproduction of factor X is achieved, there is still a significant fraction of uncarboxylated recombinant factor X. We report here that the factor X of such a cell line was only 52% carboxylated but that the fraction of carboxylated factor X could be increased to 92% by coexpressing the recently identified gene for vitamin K epoxide reductase. Because vitamin K is in excess in both the untransfected and vitamin K epoxide reductase (VKOR)-transfected cells, the simplest explanation for this result is that VKOR catalyzes both the reduction of vitamin K epoxide to vitamin K and the conversion of vitamin K to vitamin K hydroquinone. In addition to its mechanistic relevance, this observation has practical implications for overproducing recombinant vitamin K-dependent proteins for therapeutic use.
引用
收藏
页码:3811 / 3815
页数:5
相关论文
共 26 条
  • [1] Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US) - A single-arm, phase 313, multicenter study of drotrecogin alfa (activated) in severe sepsis
    Bernard, GR
    Margolis, BD
    Shanies, HM
    Ely, EW
    Wheeler, AP
    Levy, H
    Wong, K
    Wright, TJ
    Ahmed, M
    Albertson, T
    Anas, N
    Astiz, M
    Bacon, A
    Bandi, V
    Booth, F
    Bray, W
    Brilli, R
    Carlson, R
    Cheatham, M
    Conrad, S
    Cooney, R
    Cox, M
    Dolich, M
    Dries, D
    Fang, R
    Forse, R
    Fricker, R
    Givens, C
    Gomez, C
    Gottlieb, J
    Graham, D
    Cropper, I
    Cross, T
    Harrison, N
    Kearl, R
    Kearney, P
    Kinasewitz, G
    Kruse, J
    Lamberti, J
    Levy, M
    Light, R
    Lin, L
    Lisco, S
    Lo, T
    Linda, L
    Lodato, R
    Malave, L
    Martinez, A
    Mastuschak, G
    McDermott, L
    [J]. CHEST, 2004, 125 (06) : 2206 - 2216
  • [2] Enhanced γ-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide
    Camire, RM
    Larson, PJ
    Stafford, DW
    High, KA
    [J]. BIOCHEMISTRY, 2000, 39 (46) : 14322 - 14329
  • [3] VITAMIN-K AND ENERGY TRANSDUCTION - A BASE STRENGTH AMPLIFICATION MECHANISM
    DOWD, P
    HERSHLINE, R
    HAM, SW
    NAGANATHAN, S
    [J]. SCIENCE, 1995, 269 (5231) : 1684 - 1691
  • [4] ESMON CT, 1975, J BIOL CHEM, V250, P4744
  • [5] VITAMIN-K EPOXIDE AND QUINONE REDUCTASE ACTIVITIES - EVIDENCE FOR REDUCTION BY A COMMON ENZYME
    GARDILL, SL
    SUTTIE, JW
    [J]. BIOCHEMICAL PHARMACOLOGY, 1990, 40 (05) : 1055 - 1061
  • [6] Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis
    Grinnell, BW
    Joyce, D
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : S53 - S60
  • [7] Carboxylase overexpression effects full carboxylation but poor release and secretion of factor IX: Implications for the release of vitamin K-dependent proteins
    Hallgren, KW
    Hommema, EL
    McNally, BA
    Bernker, KL
    [J]. BIOCHEMISTRY, 2002, 41 (50) : 15045 - 15055
  • [9] KURTZ R, GENE EXPRESSION PROF
  • [10] LARSON AE, 1981, J BIOL CHEM, V256, P1032